Study guide

6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing

Key Takeaways Explain This Topic AI

Before using the Oregon tobacco cessation protocol, a pharmacist needs at least 2 hours of ACPE CE on tobacco cessation prescribing.

Under the Oregon tobacco protocol, patients under 18 or pregnant, nursing or planning pregnancy are referred to their PCP and 1-800-QUIT-NOW.

In the Oregon tobacco protocol, blood pressure must be taken by the pharmacist, and BP at or above 160/100 requires referral.

The Oregon tobacco protocol prefers combination NRT, starting a 14 mg patch at 10 or fewer cigarettes per day and a 21 mg patch above 10.

Seizure history, eating disorders, MAOIs or linezolid, and alcohol or sedative withdrawal rule out bupropion, and a PHQ-2 of 3 or more rules out both bupropion and varenicline.

Last updated: October 2026

Why this matters

Smoking cessation therapy is one of the patient care services ORS 689.645(1)(b) names for statewide drug therapy management protocols. The Board's Tobacco Cessation protocol (v. 06/2024) lets an Oregon pharmacist prescribe nicotine replacement therapy (NRT) , both OTC and prescription forms, and non-NRT drugs (varenicline and bupropion SR). The MPJE tests the training requirement, the screening exclusions and the dosing logic.

Training and general requirements

At least 2 hours of documented ACPE CE on pharmacist prescribing of tobacco cessation products before using the protocol.

All the general prescribing rules of OAR 855-115-0330 apply: in-person assessment, care plan, notice to the primary care provider within five business days , and seven-year records.

The patient completes the Board's Tobacco Cessation Self-Screening Patient Intake Form , and the pharmacist follows the Assessment and Treatment Care Pathway .

Screening steps that trigger referral

Step Finding Action

Background Under 18 years old , or pregnant, nursing or planning pregnancy or nursing in the next 6 months Refer to the primary care provider and the Oregon Tobacco Quit Line (1-800-QUIT-NOW)

Blood pressure Must be taken by the pharmacist . BP at or above 160/100 Refer (a second reading is allowed if the first is high)

NRT history Heart attack, arrhythmia, angina or chest pain in the past two weeks ; stomach ulcers Refer

NRT form selection Dentures or TMJ disorder: avoid gum. Chronic nasal disorder: avoid nasal spray Choose another form

Choosing NRT

Combination NRT (patch plus a short-acting form: gum, lozenge or nasal spray) is preferred .

Starting patch dose depends on total daily nicotine, counting cigarettes, e-cigarettes and chewing tobacco:

10 or fewer cigarettes per day (under about 20 mg nicotine per day): start the 14 mg/day patch .

More than 10 cigarettes per day (20 mg or more nicotine per day): start the 21 mg/day patch .

Screening for bupropion and varenicline

Before prescribing a non-NRT drug, the pharmacist reviews:

Bupropion: avoid with any history of seizure, head trauma, brain surgery, stroke or epilepsy; an eating disorder (anorexia or bulimia); use of an MAOI or linezolid ; or alcohol use or recent discontinuation of sedatives (seizure risk).

Bupropion: also avoid with chronic kidney disease, liver disease, or a mental health diagnosis or treatment in the past two years.

Varenicline: avoid , or refer if the patient still wants it, with a mental health diagnosis or treatment in the past two years, or use of an MAOI or linezolid. In the care pathway, chronic kidney or liver disease excludes bupropion but not varenicline.

Depression screening (PHQ-2): a score of 3 or more means avoid both bupropion and varenicline and refer. NRT may still be offered.

Suicide screening: any positive response requires immediate referral . The pharmacist calls the PCP's office, or uses a suicide crisis line after hours. Bupropion and varenicline may be prescribed only with a suicide-screening score of 0.

Standard pharmacotherapy facts (for counseling)

  • Drug Typical regimen Counseling points
  • Nicotine patch (21/14/7 mg) Step down every few weeks Rotate sites; remove at bedtime if vivid dreams

Gum / lozenge (2 mg, 4 mg) 4 mg if the first cigarette is within 30 minutes of waking Gum: "chew and park"; avoid acidic drinks 15 minutes before

Varenicline 0.5 mg daily ×3 days, 0.5 mg twice daily ×4 days, then 1 mg twice daily Take with food and water; reduce dose in severe renal impairment; watch mood

Bupropion SR 150 mg daily ×3 days, then 150 mg twice daily (at least 8 hours apart) Start 1–2 weeks before the quit date; insomnia; seizure risk

Behavioral support

Every pathway ends with referral to the Oregon Tobacco Quit Line (1-800-QUIT-NOW) or other cessation support, plus follow-up planning. The protocol treats counseling and support as part of the prescribing encounter, not an optional extra.

Documentation and follow-up

Each encounter produces a record under the general prescribing rules:

The completed intake form and the pharmacist's BP reading.

The care-pathway decisions and the product prescribed, with directions and quantity.

The referral or Quit Line information given.

Notice to the patient's primary care provider within five business days .

The record is kept seven years (OAR 855-104-0055). OTC nicotine products prescribed under the protocol are dispensed and labeled as prescriptions, so prescription labeling, counseling and DUR rules apply. The pharmacist plans follow-up around the target quit date: for example, adjusting NRT, stepping down patch strength, or referring if neuropsychiatric symptoms develop on varenicline or bupropion.

Note

Tobacco cessation protocol prescribing is pharmacist prescribing. A technician may not prescribe or select the therapy. A first-year intern may only observe (OAR 855-120-0150).

Exam scenario

A 42-year-old smoker of 25 cigarettes per day, with a well-controlled seizure disorder, asks for bupropion. The pharmacist measures BP at 132/84. Seizure history excludes bupropion. The pharmacist may offer combination NRT (21 mg patch plus a short-acting form), or consider varenicline if the mental health and suicide screens are negative. The pharmacist refers the patient to 1-800-QUIT-NOW, notifies the primary care provider within five business days, and documents everything for seven years. If the patient were 17 , the pharmacist would refer instead of prescribing.